Adjuvant chemotherapy vs. observation in stage I clear cell ovarian carcinoma: A systematic review and meta-analysis-Reference-Cited by-同舟云学术

Adjuvant chemotherapy vs. observation in stage I clear cell ovarian carcinoma: A systematic review and meta-analysis

Published:2020-04 Issue:1 Volume:157 Page:293-298
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Bogani Giorgio^ORCID,Ditto Antonino,Lopez Salvatore,Bertolina Francesca,Murgia Ferdinando^ORCID,Pinelli Ciro^ORCID,Chiappa Valentina,Raspagliesi Francesco

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference22 articles.

1. Cancer statistics, 2019;Siegel;CA Cancer J. Clin.,2019

2. A combined score of clinical factors and serum proteins can predict time to recurrence in high grade serous ovarian cancer;Mysona;Gynecol. Oncol.,2019

3. Histotype classification of ovarian carcinoma: a comparison of approaches;Peres;Gynecol. Oncol.,2018

4. Associations between residual disease and survival in epithelial ovarian cancer by histologic type;Melamed;Gynecol. Oncol.,2017

5. An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: an NRG Oncology/Gynecologic Oncology Group experience;Oliver;Gynecol. Oncol.,2017

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adjuvant Chemotherapy for Stage I Ovarian Clear Cell Carcinoma;O&G Open;2024-09

2. PURE vs. mixed clear cell ovarian carcinomas: Is there any impact on survival?;European Journal of Obstetrics & Gynecology and Reproductive Biology;2024-05

3. ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease;Annals of Oncology;2024-03

4. Construction of a Prediction Model of Cancer-Specific Survival after Ovarian Clear Cell Carcinoma Surgery;Clinical and Experimental Obstetrics & Gynecology;2024-01-22

5. Comprehensive characterization of genomic features and clinical outcomes following targeted therapy and secondary cytoreductive surgery in OCCC: a single center experience;Journal of Gynecologic Oncology;2024